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Methods: Expression of RORalpha isoforms was analyzed by
semi-quantitative reverse transcriptase chain reaction (RT-PCR)
and immunocytochemistry. RORalpha1 overexpression and down-
expression were achieved by the transfections of expression vec-
tor and small interfering RNA (siRNA) of RORalpha1, respectively.
Their effects on the modulation of osteoblast metabolism markers
and tumor necrosis factor alpha (TNFalpha) induced inﬂamma-
tory response markers were determined by real-time RT-PCR,
western blot, enzyme-linked immunosorbent assay, gene reporter
luciferase assay and electrophoretic mobility shift assay.
Results: The overexpression of RORalpha1 increased alkaline
phosphatase (ALP), osteocalcin (OC) and collagen type I (COL
I) mRNA and activity or protein expression, while the silenc-
ing of RORalpha1 RNA inhibited these responses. In addition,
overexpression of RORalpha1 suppressed TNFα-induced produc-
tion of cyclooxygenase-2 (COX-2), prostaglandins E2 (PGE2) and
metalloproteinase-9 (MMP-9). Upon examination of signaling path-
ways, we found that RORalpha1 was able to block TNF alpha-
induced nuclear factor kappa B (NF-kB) activation.
Conclusions: RORalpha1 is involved in human osteoblast
metabolism by stimulating osteoblast marker expression and in-
hibiting inﬂammatory responses. These ﬁndings may encourage
further exploration of RORalpha1 as a potential target for the
treatment of bone disorders related to inﬂammation.
162
A LOWER OSTEOPROTEGERIN/RANKL RATIO IS
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Purpose: In previous studies, we have observed that prior sub-
chondral bone (SB) osteoporosis (OP) aggravated the cartilage
damage in a combined model of OP and osteoarthritis (OA) in
rabbits (Calvo et al. Osteoarthritis Cartilage 15:69-77, 2007). In
this work, our aim was to study whether an increased SB remod-
eling could account for the increased cartilage damage in rabbits
with OA aggravated by prior subchondral OP.
Methods: OP was induced in 20 (8 month-old; 3.5-4.8 kg body
weight), skeletally mature female NZ rabbits, by ovariectomy (OVX)
and intramuscular injections of methylprednisolone hemisuccinate
(1 mg/kg/day for 4 weeks; OP group). Ten age and gender-
matched additional animals were used as controls. Surgical OA
was simultaneously induced in the left knees of all the rabbits
through partial medial meniscectomy and anterior cruciate liga-
ment transection. The animals were sacriﬁced 22 weeks after
OVX. Then, left knees were considered as OA or as OA plus
OP (OPOA) and the right knees were used as OP or healthy
controls, respectively. The percentage of bone area/tissue area
(BAr/TAr) was assessed in the SB of the femurs after sacri-
ﬁce by micro- Computed Tomography. Osteoprotegerin (OPG),
RANKL and MMP-9 protein synthesis at the SB were evaluated
by western-blot studies. Nonpair-wise statistical comparisons were
done using Mann-Whitney test for the different variables studied
and correlations by Spearman’s test (SPSS vs. 15).
Results: At sacriﬁce, the BAr/TAr in the SB was signiﬁcantly di-
minished in OP, OA and OPOA knees when compared to healthy
knees (p<0.05), although a greater decrease was observed in the
OPOA knees (p<0.05 vs. OP and vs. OA). At SB, the OPG/RANKL
protein synthesis ratio was signiﬁcantly diminished in OA, OP
and OPOA knees when compared to healthy controls (Healthy:
1.36±0.14; OA: 1±0.02*; OP: 0.91±0.1*; OPOA: 0.7±0.04* ar-
bitrary units; *p<0.05 vs. healthy), although it was signiﬁcantly
lower in OPOA knees when compared to OP or to OA (p<0.05 for
both comparisons). MMP-9 protein synthesis in the SB was signif-
icantly increased both in OA and in OPOA knees in comparison
to healthy knees (Healthy: 100±7; OA: 362±90*; OP: 284±80;
OPOA: 690±180* arbitrary units; *p<0.05 vs. healthy). Further-
more, a signiﬁcantly greater increase was observed for OPOA
knees in comparison to OA knees. In addition, we observed a
positive correlation between BAr/TAr and OPG/RANKL ratio in the
SB of these rabbits (r=0.911; p=0.001).
Conclusions: The remodeling parameters BAr/TAr, OPG/RANKL,
both analyzed in the SB, were diminished in OA, OP and even
more in OPOA. In the same way, the MMP-9 synthesis was greater
in OPOA than in OA rabbits. Our results show that an increased
SB remodeling can be responsible for the severity of cartilage
damage in OA, at least in rabbits with prior OP. This ﬁnding can be
relevant since these pathologies are frequently found in the same
patients, in which OP can precede OA onset.
163
OSTEOCLAST PHENOTYPE AND RESORPTIVE ACTIVITY
ARE MODIFIED DISTINCTLY BY DIFFERENT TYPES OF
OSTEOCLAST INHIBITORS - IMPLICATIONS FOR
OSTEOCLAST QUALITY?
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Purpose: Osteoarthritis (OA) is described as being a disorder that
has its origin in bone and cartilage. It is therefore interesting to
investigate the biological action of bone resorping cells also known
as the osteoclasts. Osteoclast inhibition can be used to investigate
the biological processes underlying bone remodeling; however the
direct effect on osteoclast phenotype caused by modulation of
both the organic and inorganic phase of bone during resorption
has not been investigated in detail. The aim of the current study
was to investigate the phenotype of resorptive human osteoclasts
after treatment with different types of inhibitors and thereby gain
more knowledge about bone turnover.
Methods: Mature human osteoclasts, generated from CD14+
monocytes, were seeded on bone slices and treated with inhibitors
of acidiﬁcation (baﬁlomycin; diphyllin; ethoxyzolamide), inhibitors
of proteolysis (E64 [cat. K inhibitor]; GM6001 [MMP inhibitor]) or a
bisphosphonate (Ibandronate). Bone resorption was measured by
Ca2+ (inorganic), CTX-I (organic), ICTP (organic, MMP generated)
and pit scoring. In addition, gelatinase activity and the osteoclast
marker TRACP were measured.
Results: All inhibitors of acidiﬁcation were equally potent with
respect to inhibition of organic and inorganic resorption, measured
both by resorption markers and pit scoring. Conversely, E64 ef-
fectively reduced organic resorption by 80%, whereas inorganic
resorption was modestly reduced. Resorbed bone area, ICTP
release and gelatinase activity were all increased for this treat-
ment. Treatment with GM6001 had no effect on neither organic
nor inorganic resorption alone; however, when combined with E64
degradation of the organic phase of bone was abrogated, whereas
inorganic resorption was reduced by 60%. Ibandronate completely
abrogated both organic and inorganic resorption, while TRACP
activity was strongly decreased.
Conclusions: Inhibitors of acidiﬁcation and Ibandronate potently
reduced both organic and inorganic resorption to the same level.
In face of that, inhibition of proteolysis leads to potent reduction
of organic resorption, but only modest reduction of inorganic
resorption, and even an increased resorbed bone area, possibly
due to MMP mediated compensation. These ﬁndings strongly
indicate that different anti-osteoclastic intervention strategies affect
